New Gene Target for Treatment-Resistant Brain Cancer
Complete the form below to unlock access to ALL audio articles.
Doctors and scientists at UCLA Jonsson Comprehensive Cancer Center and the UCLA Jane and Terry Semel Institute for Neuroscience and Human Behavior have identified a gene that may provide a therapeutic target for the deadly, treatment-resistant brain cancer glioblastoma multiforme.
The gene, P300, enables cancer cells that have been damaged by radiation therapy to recover by rearranging DNA and initiating a molecular mechanism that refortifies tumor cells for growth and survival.
In studies using mice and in human glioblastoma multiforme cells, the scientists discovered that blocking P300 disrupted its ability to set that process in motion. The research is published online in Nature Communications.
Glioblastoma is considered rare — about 13,000 new cases are expected to be diagnosed in the U.S. this year, according to the National Brain Tumor Society — but it is the most common primary brain tumor in adultsm, and there is no known cure. Glioblastoma multiforme cells and their precursors, glioma stem cells, quickly adapt and recover from injury, so chemotherapy and radiation therapy, which may initially slow a tumor’s progress, can ultimately contribute to growth and recurrence.
Reference: Muthukrishnan SD, Kawaguchi R, Nair P, et al. P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells. Nat Comms. 2022;13(1):6202. doi: 10.1038/s41467-022-33943-0.
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.